Page 23 of 29
PH10.16 | PH10.16 | Cautious Prescribing for Dependence-Producing Drugs — SDL Guide — SDL Guide (Part 2)
Applied Practice: Prescribing Decisions in Clinical Scenarios
Applying the cautious prescribing framework to real clinical scenarios builds the decision-making pattern that protects both patients and prescribers.
Scenario 1 — Opioid prescribing for cancer pain (appropriate high-dose use):
A 65-year-old woman with metastatic breast cancer has severe bone pain (NRS 8/10) uncontrolled on NSAIDs and paracetamol. Morphine is indicated.
Decision framework: Indication — severe cancer pain with objective severity and failed non-opioid analgesia: Yes, indication is clear. Dose: start with oral immediate-release morphine 5–10 mg every 4 hours, with a rescue dose of the same for breakthrough pain. Duration: indefinite, titrated to pain control. Monitoring: pain scores at each review; side effects (constipation — prescribe laxative prophylactically; nausea — antiemetic if needed; sedation — dose-timing adjustment). There is no arbitrary upper dose limit in cancer pain — the right dose is the dose that controls pain without unacceptable toxicity. Regular scheduled doses with rescue provision is the WHO pain ladder standard.
Prescription format: morphine is Schedule X — prescription in duplicate, quantity in words, patient address, prescriber registration number required.
Scenario 2 — Benzodiazepine for acute anxiety:
A 35-year-old teacher has a panic attack before a major exam presentation. She requests diazepam.
Decision: benzodiazepines for short-term acute anxiety have a limited, specific role. In a single-episode performance anxiety context: consider whether propranolol (a beta-blocker, non-scheduled, without dependence potential) would adequately address the somatic symptoms (tremor, palpitations) — often preferred for performance anxiety over benzodiazepines. If benzodiazepines are necessary: prescribe a single low dose (diazepam 2–5 mg) with a clear 'single use only' communication; document this is for acute, one-time use; do not repeat the prescription. Inform the patient about sedation (do not drive) and that regular use would be medically inappropriate.
Scenario 3 — Refusing a benzodiazepine repeat (dependence management):
The alprazolam patient from the hook scenario — 18 months on alprazolam 0.5 mg BD with withdrawal symptoms on missed doses — presents for renewal.
Decision: This patient has physical dependence and the alprazolam must not be continued at the same dose indefinitely, but must also not be stopped abruptly (seizure risk from benzodiazepine withdrawal). The appropriate management:
1. Acknowledge the withdrawal symptoms are genuine physiological dependence — do not dismiss or accuse
2. Convert the alprazolam to an equivalent diazepam dose (for smoother tapering): alprazolam 1 mg/day ≈ diazepam 10–20 mg/day equivalent
3. Initiate a structured tapering schedule (reduce diazepam by ~10–25% every 2–4 weeks)
4. Provide concurrent support: refer for CBT for anxiety; consider SSRI/SNRI (evidence-based for anxiety disorders without dependence potential)
5. If specialist psychiatry or de-addiction input is needed, facilitate referral
SELF-CHECK
A patient who has been on diazepam 10 mg nocte for 9 months for insomnia says he wants to stop completely and asks if he can just stop taking it. What is the MOST appropriate advice?
A. A) Yes, abrupt discontinuation is safe since diazepam has a long half-life
B. B) No — abrupt discontinuation after 9 months of regular use can cause severe benzodiazepine withdrawal including generalised tonic-clonic seizures; a supervised gradual tapering schedule is required
C. C) Yes, abrupt discontinuation is safe as long as he has no history of epilepsy
D. D) He should switch to alprazolam and taper from there — it is easier to stop
Reveal Answer
Answer: B. B) No — abrupt discontinuation after 9 months of regular use can cause severe benzodiazepine withdrawal including generalised tonic-clonic seizures; a supervised gradual tapering schedule is required
B is correct. Benzodiazepine withdrawal after prolonged use (months) can be life-threatening — symptoms include anxiety, insomnia, tremor, diaphoresis, and in severe cases, generalised tonic-clonic seizures and delirium. This is not mitigated by the long half-life of diazepam (which only slows the onset of withdrawal, not its severity). A supervised tapering schedule — typically reducing by 10–25% of dose every 2–4 weeks — is the standard of care. Option A is incorrect: long half-life slows but does not prevent withdrawal. Option C is wrong: prior epilepsy status is irrelevant; benzodiazepine withdrawal can provoke seizures in individuals without a seizure history. Option D is incorrect: alprazolam has a shorter half-life than diazepam and is associated with more severe, faster-onset withdrawal — switching to alprazolam for tapering would be more difficult, not easier.
Evaluating Dependence Risk and When to Refer
Identifying patients at elevated risk of developing dependence before prescribing allows proactive risk mitigation. Identifying established dependence in a patient already prescribed these drugs triggers a structured management and referral pathway.
Pre-prescribing risk assessment:
For any patient about to receive opioids or benzodiazepines, quickly screen for the main risk factors:
- Personal or family history of substance use disorder (highest risk factor)
- Current or past alcohol misuse
- History of smoking
- Young age (<40 for opioids)
- Psychiatric comorbidity (depression, PTSD, personality disorder) — strong predictor of opioid misuse
- Social instability (housing, employment insecurity)
The ORT (Opioid Risk Tool) is a validated 5-item self-report tool that classifies patients as low (<3), moderate (4–7), or high risk (>7) for opioid misuse. For benzodiazepines, similar risk stratification applies.
Recognising aberrant drug-taking behaviour:
Clinical red flags suggesting dependence development or misuse:
- Repeated requests for early prescription refills ('I lost my tablets' repeatedly)
- Multiple prescribers for the same drug (doctor shopping)
- Requesting a specific drug by name rather than describing symptoms
- Using the drug for a non-prescribed purpose (opioids for mood/sleep rather than pain)
- Dose escalation beyond the agreed plan without consulting the prescriber
- Deteriorating function (missed work, relationship breakdown) concurrent with dose escalation
When and how to refer:
Indications for referral to psychiatry or de-addiction services:
- Established opioid use disorder — particularly for buprenorphine/naloxone (OSAT programme) or methadone maintenance
- Benzodiazepine dependence requiring specialist-supervised tapering
- Polydrug dependence (opioid + alcohol + benzodiazepine)
- Failure to taper despite structured attempts in primary care
- Active suicidal ideation associated with substance use
Harm reduction in the interim:
If a patient is dependent and not yet in formal treatment, harm reduction principles apply: ensure safe storage of opioids (away from children); prescribe naloxone (opioid antagonist) and educate the patient and family on its use in case of overdose; avoid prescribing multiple CNS depressants concurrently (opioid + benzodiazepine + alcohol greatly increases overdose risk).
CLINICAL PEARL
Benzodiazepine withdrawal seizures can be fatal — never stop abruptly after chronic use. Unlike opioid withdrawal (intensely unpleasant but rarely fatal in otherwise healthy patients), benzodiazepine withdrawal from long-term use shares the life-threatening profile of alcohol withdrawal. The underlying mechanism is the same: GABA-A receptor downregulation during chronic use → rebound CNS hyperexcitability on cessation → seizures. A patient who abruptly stops diazepam after 6+ months of daily use can have a seizure 2–7 days after the last dose. Always taper, never stop abruptly, and consider hospital admission for patients with very high dose dependence.
Self-Assessment: Cautious Prescribing for Dependence-Producing Drugs
Work through these structured exercises to consolidate your cautious prescribing skills.
Exercise 1 — Opioid risk assessment:
A 45-year-old man presents with chronic low back pain after a workplace injury 2 years ago. Physiotherapy has not helped adequately. His colleague is on tramadol and reports it works well. He asks for a tramadol prescription.
Apply the cautious prescribing framework:
1. Indication: Chronic non-cancer pain is a complex area — opioids are generally not recommended as first-line for chronic low back pain by current guidelines (physio + NSAIDs + duloxetine/pregabalin preferred). Is there documented severity and failed non-opioid trials?
2. Risk assessment: Does he have a history of alcohol use, psychiatric comorbidity, or substance misuse? What is his ORT score?
3. If prescribing: Tramadol is Schedule H1 — standard prescription with documentation. Start at the lowest dose (50 mg TID); set a clear treatment trial of 4 weeks with a pain score and functional assessment at review; do not escalate without objective improvement documented; set a maximum duration with taper plan.
4. Alternatives: Has he had a trial of an SNRI (duloxetine, which has RCT evidence for chronic low back pain) or a supervised physiotherapy/pain clinic programme?
Exercise 2 — Benzodiazepine tapering plan:
A patient on diazepam 20 mg daily for 12 months wants to stop. Calculate a tapering schedule and name the concurrent non-pharmacological support that should be offered.
Model tapering schedule:
Reduce by 2.5 mg (approximately 10–12.5%) every 2 weeks (slower if withdrawal symptoms appear):
Week 0–2: 17.5 mg/day → Week 3–4: 15 mg/day → Week 5–6: 12.5 mg/day → ... continuing until 0. At doses below 5 mg, slowing to 1 mg reductions per 2 weeks is often needed. Total duration: approximately 6–9 months for this dose.
Concurrent support: CBT for anxiety or insomnia (the original indication); patient education about withdrawal symptoms and that they will resolve; regular weekly or 2-weekly review during the taper; consider referral to clinical psychology or a specialist benzodiazepine tapering clinic if available.